Included in this issue of the Proceedings are five articles describing progress in total genome analysis of five higher eukaryotes. Collections of reviews and discussions of this sort are a new feature of the Proceedings and are intended to provide a broader perspective of a particular field than could be obtained in a single review.
The choice of the Genome Project as a topic for such a set of reviews is timely, as the Project officially reached its fifth birthday in the United States on October 1, 1995. Discussions about the wisdom and feasibility of undertaking to map and sequence all of the chromosomes of Homo sapiens began in the mid-1980s and led to appropriately intense scientific debate before this international effort coalesced in 1990. That early period of debate and discussion has served the project well, as it provided an opportunity for the definition of a clear set of milestones based on realistic scientific opportunities. The initial set of goals (1) , which were expected to cover the interval from October 1990 to September 1995, was revised in 1993 (2) due to rapid advances in several of the critical technologies. In the United States, the hoped-for budget of $200 million per year (in 1990 dollars) never quite materialized; the project has been operating at about 70% of this level for the past 2 years. Nonetheless, nearly all of the initial milestones set for the project have been met or exceeded (3) .
Model Organisms
The original planners of the Human Genome Project concluded that to carry out such an effort for Homo sapiens alone would be a major blunder. The comparison of map and sequence information across species, especially for model organisms with a rich background of genetics and biology, was predicted to add much greater value to the information than would derive from the human sequence alone. Furthermore, the density of genes per unit length of DNA is substantially higher for many simpler organisms than it is for the human ( Table 1 ), such that projects devoted to simpler genomes might be expected to yield greater information per dollar expended in the early phases of the effort than tackling the dauntingly complex genomes of mammals. Hardly a day passes when the wisdom of this strategy is not now evident. A recent example is the identification of the gene responsible for ataxia telangiectasia (A-T) in humans (4) . A-T is a rare autosomal recessive disease in which affected children suffer from neurologic deterioration, immune deficiency, a high risk of cancer, and radiation sensitivity. An arduous positional-cloning strategy eventually yielded the responsible gene, denoted ATM for "Mutated in A-T." A computer search of sequence data bases revealed that the strongest similarity for this previously uncloned human gene was to a yeast sequence derived from genomic sequencing of yeast chromosome II. Mutations of this gene revealed strong similarities to the human phenotype, including sensitivity to y-rays and certain drugs (5, 6).
The collection of papers in this issue focuses on higher eukaryotes. Absent from the collection are reviews on bacteria and yeast, but that should not be taken as an indication of lack of activity. Quite to the contrary, 1995 has seen the publication of the first complete sequence of a free-living organism, namely Haemophilus influenzae, which was assembled by using a total genomic shotgun strategy applied to its 1.8-Mb genome (7). Other complete prokaryotic DNA sequences are expected to follow soon, with the sequence ofE. coli (4.2 Mb) on track for completion in 1997 and that of Bacillus subtilis (4.2 Mb) also expected to be finished that year. Progress for S. cerevisiae has been dramatic, with completion of its 1.5-Mb sequence expected within 6 to 9 months, thanks in large part to a consortium of European groups.
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In the following pages, the reader can obtain a timely snapshot of the progress in total genome analysis for Arabidopsis (8) , the roundworm C. elegans (9), Drosophila (10), the mouse (11), and human (12) . As expected, progress toward completion is inversely related to genome size. Of the first three, all of which have genome sizes of 100-120 Mb, C. elegans is farthest along, and its sequence is likely to be completed by 1998, thanks to a highly organized and efficient mapping and sequencing effort.
As for the mouse, it is apparent that the 
A very important recent step has been the initiation of a rat genome project, cosponsored by all of the Institutes of the National Institutes of Health (with strong leadership from the National Heart, Lung, and Blood Institute) to support the creation of a dense rat genetic map, a series of large-insert rat genomic libraries, and a set of rat cDNA libraries. This cooperative effort may provide a paradigm for initiating additional genome projects on other important organisms, such as Schizosaccharomyces pombe, zebrafish, pufferfish, or dog. Such projects might not necessarily include a commitment to total genome sequencing, although in the case of simpler organisms, this would be an attractive feature.
The Human Genome
Progress in mapping and sequencing in the human has also been gratifying (12) . The genetic map is in excellent shape, the physical map is coming together nicely, and attention now shifts toward scaling-up genomic sequencing (13) . The National Center for Human Genome Research recently issued a Request For Applications which invited applicants to propose "pilot" genomic sequencing projects on human DNA which would result in a throughput of tens of megabases per year by the third year, and a gratifying number of ambitious proposals have been received. Over the next 18 months, it is likely that a much better sense will emerge about the difficulties in accomplishing this scaleup, and, as a consequence, it is likely that a new 5-year plan will be needed by 1997.
Expressed Sequences
An important parallel effort for most of the organisms listed in Table 1 has been the sequencing of the ends of large numbers of cDNA clones. Such sequences are commonly referred to as expressed sequence tags (ESTs). Sequencing a large number of such ESTs, especially from normalized cDNA libraries, is likely to provide information about a significant fraction of the total number of transcripts produced by a given organism. Many of these will not be full length, however, and a significant fraction of genes (especially those expressed at very low levels or in very restricted tissues or developmental time frames) will be poorly represented. Nonetheless, the collection of such sequences provides interesting information about the array of motifs utilized by a organism. Such ESTs are of much greater utility, however, if they are precisely mapped, so that investigators engaged in positional cloning have the opportunity to short circuit what otherwise can be a rather arduous effort of gene hunting in a candidate interval. The recent funding of a major human EST-sequencing effort by Merck, for which the sequences are being deposited immediately in a freely accessible, public data base (14) , has produced a wealth of useful information and has catalyzed the formation of a consortium of investigators devoted to placing these ESTs on the physical map as quickly as possible. This will undoubtedly accelerate the pace of discovery of genes for human illnesses and other important traits.
Ethical, Legal, and Social Implications (ELSI) While the Human Genome Project does notper se introduce any brand new ethical, legal, or social dilemmas, the acceleration of the pace of genetic discovery fully justifies the wisdom of inclusion of the ELSI program. Divided between a research portfolio and a policy arm (the ELSI Working Group), the ELSI program has moved from an earlier phase of defining issues and recruiting experts to its current focused agenda surrounding risks of genetic discrimination in employment and health insurance, the safety and efficacy of new tests being contemplated for introduction into clinical practice, privacy of genetic information, issues surrounding informed consent, and the need for better public and professional education. Progress is being made on all these fronts, but the importance of continued innovative strategies to encourage the beneficial use of genetic information, and discourage its misuse, cannot be overstated.
Looking Toward the Future
Given the current progress in these various genome projects, it is not too soon to begin to think about what biomedical research will look like after the completion of the first human genome sequence (currently estimated to occur around 2002 or 2003). This will be only the "end of the beginning" of the era of sequenced-based biology, and continuous improvements in capabilities for large-scale sequence analysis, placing megabase sequencing in the hands of an average laboratory, are to be expected. Certain intermediate tools of the genome project, such as specific largeinsert libraries, will have a limited lifetime. What will endure will be the sequence itself, as well as polymorphisms which make up the genetic map and allow the localization of important phenotypes. It seems unlikely that the current microsatellite maps, which require gel analyses for genotyping, will turn out to be optimal in the long run. Single nucleotide polymorphisms, while less informative, are much more adaptable to automated scoring and a denser array of such polymorphisms is likely to become the genetic map of choice in the future. There will undoubtedly be continuing need for genome-wide approaches to biology, even after completion of the first human sequence. Such genome-wide approaches will include functional analyses that are applicable to large numbers of genes in a single screen [as exemplified by the P element project described in the accompanying article on Drosophila (10)], studies of diversity and variability within a species, and improvements in technology, both for sequencing and for genotyping. Close attention to the ways in which the availability of totalgenome sequence alters the practice of biological research in prokaryotes and yeast over the next 2 or 3 years is likely to presage what will happen after the turn of the century for mammals.
It seems likely that historians of science writing about the genome project a century from now will point to this era as a particularly significant one in our understanding of biology and medicine. In fact, it is difficult to identify other organized scientific adventures carrying such profound significance for ourselves and our society. Yet, when this project is completed, there will be decades, if not centuries, of vigorous and creative scientific effort still ahead to understand the function of these blueprints. There will be no danger of a lull in biomedical science.
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